EU Approvals Beckon For Inrebic & Novel Adalimumab Biosimilar
TETEC Withdraws EU Filing for ATMP For Cartilage Defects
Inrebic, Celgene’s myelofibrosis treatment, and Yuflyma, Celltrion’s high-concentration adalimumab biosimilar, are among the latest new drugs that have been recommended for approval for use across the EU. Meanwhile, TETEC has withdrawn its EU marketing application for Artobend.
